AU2015369854B2 - Anti-CSF1R antibodies for treating PVNS - Google Patents

Anti-CSF1R antibodies for treating PVNS Download PDF

Info

Publication number
AU2015369854B2
AU2015369854B2 AU2015369854A AU2015369854A AU2015369854B2 AU 2015369854 B2 AU2015369854 B2 AU 2015369854B2 AU 2015369854 A AU2015369854 A AU 2015369854A AU 2015369854 A AU2015369854 A AU 2015369854A AU 2015369854 B2 AU2015369854 B2 AU 2015369854B2
Authority
AU
Australia
Prior art keywords
antibody
seq
dose
csf1r
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015369854A
Other languages
English (en)
Other versions
AU2015369854A1 (en
Inventor
Julie Hambleton
Nilacantan SANKAR
Robert Sikorski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Five Prime Therapeutics Inc
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of AU2015369854A1 publication Critical patent/AU2015369854A1/en
Application granted granted Critical
Publication of AU2015369854B2 publication Critical patent/AU2015369854B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2015369854A 2014-12-22 2015-12-21 Anti-CSF1R antibodies for treating PVNS Ceased AU2015369854B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462095297P 2014-12-22 2014-12-22
US62/095,297 2014-12-22
US201562163251P 2015-05-18 2015-05-18
US62/163,251 2015-05-18
PCT/US2015/067012 WO2016106180A1 (en) 2014-12-22 2015-12-21 Anti-csf1r antibodies for treating pvns

Publications (2)

Publication Number Publication Date
AU2015369854A1 AU2015369854A1 (en) 2017-06-15
AU2015369854B2 true AU2015369854B2 (en) 2021-07-01

Family

ID=55135539

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015369854A Ceased AU2015369854B2 (en) 2014-12-22 2015-12-21 Anti-CSF1R antibodies for treating PVNS

Country Status (16)

Country Link
US (3) US10040858B2 (enExample)
EP (1) EP3237447B1 (enExample)
JP (1) JP6797801B2 (enExample)
KR (1) KR20170096187A (enExample)
CN (1) CN107257806B (enExample)
AU (1) AU2015369854B2 (enExample)
BR (1) BR112017013111A2 (enExample)
CA (1) CA2969341C (enExample)
EA (1) EA201791421A1 (enExample)
ES (1) ES2843586T3 (enExample)
HK (1) HK1245804A1 (enExample)
IL (1) IL252716A0 (enExample)
MX (1) MX2017008218A (enExample)
SG (1) SG11201704792UA (enExample)
TW (1) TW201630937A (enExample)
WO (1) WO2016106180A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201803905A (zh) 2016-06-20 2018-02-01 克馬伯有限公司 用於免疫腫瘤學之多重專一性抗體
JP2020517256A (ja) 2017-04-19 2020-06-18 エルスター セラピューティクス， インコーポレイテッド 多重特異性分子およびその使用
JP7348899B2 (ja) 2017-12-08 2023-09-21 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性分子及びその使用
CN112423780A (zh) * 2018-03-05 2021-02-26 诗彭斯眼科研究所公司 通过靶向集落刺激因子进行的青光眼和视神经病变的治疗
CN108948199B (zh) * 2018-07-18 2019-06-21 博奥信生物技术（南京）有限公司 抗人csf-1r单克隆抗体及其用途
CN109053887B (zh) * 2018-07-18 2019-07-23 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及用途
JP2021534101A (ja) 2018-08-09 2021-12-09 ヴェルソー セラピューティクス， インコーポレイテッド Ｃｃｒ２及びｃｓｆ１ｒを標的とするためのオリゴヌクレオチド組成物ならびにその使用
CA3109702A1 (en) 2018-08-13 2020-02-20 Signablok, Inc. Peptides and compositions for targeted treatment and imaging
CN112822999A (zh) * 2018-09-13 2021-05-18 豪夫迈·罗氏有限公司 Csf-1r抗体制剂
JP7465272B2 (ja) 2018-09-27 2024-04-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体
CA3140914A1 (en) * 2019-05-24 2020-12-03 Elixiron Immunotherapeutics (hong Kong) Limited Anti-csf1r antibodies, il10 fusion proteins, and uses thereof
WO2021087105A1 (en) 2019-10-30 2021-05-06 Duke University Immunotherapy with combination therapy comprising an immunotoxin
US11419822B2 (en) * 2020-12-14 2022-08-23 AmMax Bio, Inc. High concentration formulations of anti-CSF1 and anti-CSF1R antibodies
EP4587059A2 (en) * 2022-09-12 2025-07-23 Ammax Bio, Inc Treatment of tenosynovial giant cell tumor
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN118593504B (zh) * 2024-06-03 2025-03-18 北京大学第三医院（北京大学第三临床医学院） 氘可来昔替尼或其盐在制备pvns药物方面的新用途
WO2025257419A1 (en) * 2024-06-13 2025-12-18 4Moving Biotech Glp-1 receptor agonist compounds for treating a proliferative synovial disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206715B2 (en) * 2010-05-04 2012-06-26 Five Prime Therapeutics, Inc. Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0382781B1 (en) 1987-10-23 1993-09-29 Genetics Institute, Inc. Composition for treating cancers characterized by over-expression of the c-fms proto-oncogene
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5866114A (en) 1992-06-09 1999-02-02 Chiron Corporation Crystallization of M-CSFα
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
AU1804499A (en) 1997-12-05 1999-06-28 La Jolla Institute For Experimental Medicine Inhibition of tumor growth by macrophage intervention
CA2348292A1 (en) 1998-10-30 2000-05-11 Takeda Chemical Industries, Ltd. Betacellulin protein-containing preparation
PT1223980E (pt) 1999-10-28 2003-10-31 Reinhold Hofbauer Utilizacao de inibidores de csf-1
AU1759501A (en) 1999-11-08 2001-06-06 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Method of treating a viral infection using antagonists of macrophage colony stimulating factor
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
US6773895B2 (en) 2000-09-01 2004-08-10 Boehringer Ingelheim Pharma Kg Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
US7247618B2 (en) 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
JP2005500034A (ja) 2001-06-20 2005-01-06 プロション バイオテク リミテッド 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
PT1572106E (pt) 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic Métodos para prevenção e tratamento de metástase de cancro e perda óssea associada a metástase de cancro
US7807389B2 (en) 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
NZ547279A (en) 2003-10-22 2008-04-30 Keck Graduate Inst Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
GB0325836D0 (en) 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
WO2005070447A2 (en) 2004-01-21 2005-08-04 Chiron Corporation M-csf muteins and uses thereof
WO2005113596A2 (en) 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
EP2479277B1 (en) 2004-07-22 2015-09-02 Five Prime Therapeutics, Inc. Use of MGD-CSF in a method of treatment of Alzheimer's disease.
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
ATE454455T1 (de) 2005-01-27 2010-01-15 Five Prime Therapeutics Inc Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP1945662A2 (en) 2005-11-10 2008-07-23 Receptor Biologix, Inc. Methods for production of receptor and ligand isoforms
WO2007075933A2 (en) 2005-12-21 2007-07-05 Cell Signaling Technology, Inc. Translocation and mutant csf1r kinase in human leukemia
KR101358600B1 (ko) 2005-12-22 2014-02-06 조마 테크놀로지 리미티드 가용성 인간 ｍ-ｃｓｆ 수용체 및 이의 용도
US20090246208A1 (en) 2006-01-05 2009-10-01 Novartis Ag Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
HUE035654T2 (en) 2006-04-19 2018-05-28 Novartis Ag 6-o-substituted benzoxazole and benzothiazole compounds and methods for inhibiting CSF-1R signaling
EP2423226A3 (en) 2006-11-10 2012-05-30 Amgen Inc. Antibody-based diagnostics and therapeutics
WO2008060610A2 (en) 2006-11-17 2008-05-22 Biogen Idec Ma Inc. Systemic administration of colony stimulating factors to treat amyloid associated disorders
DE602008004296D1 (de) 2007-02-14 2011-02-17 Vaccinex Inc Humanisierte anti-cd100-antikörper
WO2008124858A2 (en) 2007-04-11 2008-10-23 F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. Targeted receptor
ES2452349T3 (es) 2007-05-21 2014-04-01 Novartis Ag Inhibidores de CSF-1R, composiciones, y métodos de uso
US20100298217A1 (en) 2007-05-30 2010-11-25 Evan Richard Stanley Csf-1r mutants
HUE037265T2 (hu) 2007-08-21 2018-08-28 Amgen Inc Humán c-fms antigént kötõ proteinek
US7981415B2 (en) 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
MX2010004246A (es) 2007-10-18 2010-04-30 Novartis Ag Inhibidores de csf-1r para el tratamiento de cancer y de enfermedades oseas.
EP2215482A2 (en) 2007-10-31 2010-08-11 Janssen Pharmaceutica N.V. Biomarker for assessing response to fms treatment
WO2009075344A1 (ja) 2007-12-12 2009-06-18 Japan As Represented By Director General Of Agency Of National Cancer Center M-csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用
EP2262836B1 (en) 2008-03-14 2016-03-09 Transgene SA Antibody against the csf-1 r
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
CA2727389A1 (en) 2008-06-10 2009-12-17 Prabha N. Ibrahim 5h-pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
US8080246B2 (en) 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
EP2496086B1 (en) 2009-11-06 2017-05-31 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
RS58693B1 (sr) 2009-12-10 2019-06-28 Hoffmann La Roche Antitela koja poželjno vezuju ekstracelularni domen 4 humanog csf1r, i njihova primena
HRP20140770T1 (hr) 2009-12-21 2014-11-07 Array Biopharma, Inc. SUPSTITUIRANI SPOJEVI N-(1H-INDAZOL-4-IL)IMIDAZO[1,2-a]PIRIDIN-3-KARBOKSAMIDA KAO INHIBITORI CFMS
CN102918060B (zh) 2010-03-05 2016-04-06 霍夫曼-拉罗奇有限公司 抗人csf-1r抗体及其用途
BR112012022046A2 (pt) 2010-03-05 2017-02-14 F Hoffamann-La Roche Ag ''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''.
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
AR084234A1 (es) 2010-12-13 2013-05-02 Novartis Ag Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17)
RU2639553C2 (ru) 2011-10-21 2017-12-21 Трансжене Са Модуляция активации макрофагов
EP2768861A1 (en) 2011-10-21 2014-08-27 Institut National de la Sante et de la Recherche Medicale (INSERM) A m-dc8+ monocyte depleting agent for the prevention or the treatment of a condition associated with a chronic hyperactivation of the immune system
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
AU2013238126C1 (en) * 2012-03-26 2018-06-14 Nippon Chemiphar Co., Ltd. Prophylactic or therapeutic agent for giant cell tumors occurring in bone and soft tissue or for chondrosarcoma
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AU2012374617B2 (en) 2012-05-11 2015-09-17 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
CN104684582A (zh) 2012-08-31 2015-06-03 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206715B2 (en) * 2010-05-04 2012-06-26 Five Prime Therapeutics, Inc. Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RIES CAROLA H ET AL, Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy, CANCER CELL, PAGE(S) 846 - 859, (2014-06-16), ISSN 1535-6108 *

Also Published As

Publication number Publication date
US10040858B2 (en) 2018-08-07
TW201630937A (zh) 2016-09-01
WO2016106180A1 (en) 2016-06-30
JP2018501254A (ja) 2018-01-18
US20160185869A1 (en) 2016-06-30
SG11201704792UA (en) 2017-07-28
US20190119390A1 (en) 2019-04-25
JP6797801B2 (ja) 2020-12-09
CN107257806A (zh) 2017-10-17
CN107257806B (zh) 2021-08-10
US10730949B2 (en) 2020-08-04
CA2969341A1 (en) 2016-06-30
EP3237447B1 (en) 2020-12-02
AU2015369854A1 (en) 2017-06-15
HK1245804A1 (zh) 2018-08-31
IL252716A0 (en) 2017-08-31
MX2017008218A (es) 2017-10-18
KR20170096187A (ko) 2017-08-23
ES2843586T3 (es) 2021-07-19
CA2969341C (en) 2023-07-04
BR112017013111A2 (pt) 2018-05-15
EA201791421A1 (ru) 2017-10-31
US20210009700A1 (en) 2021-01-14
EP3237447A1 (en) 2017-11-01

Similar Documents

Publication Publication Date Title
AU2015369854B2 (en) Anti-CSF1R antibodies for treating PVNS
US20230052212A1 (en) Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
US10822421B2 (en) Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
US20210277130A1 (en) Methods of Treating Conditions with Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R)
AU2018269984B2 (en) Anti-FGFR2 antibodies in combination with chemotherapy agents in cancer treatment
JP5513888B2 (ja) グルカゴン受容体抗体に関する組成物および方法
KR20200011616A (ko) 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
CN118924895A (zh) 用于癌症治疗的结合her2、nkg2d和cd16的多特异性结合蛋白的药物制剂和剂量方案
KR20170016501A (ko) 콜로니 자극 인자 1 수용체 (ｃｓｆ1ｒ)에 결합하는 항체를 이용하여 병태를 치료하는 방법
TW201839009A (zh) 使用抗人類ｇｐｖｉ抗體抑制血小板凝集
EA040840B1 (ru) Антитела против csf1r для лечения pvns

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired